Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension

Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension - Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027411

Enrollment

Registered

2017-06-01

Start date

2017-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1,pulmonary hypertension Group 1:pulmonary arterial hypertension (PAH) Group 2:pulmonary hypertension due to left heart disease Group 3:pulmonary hypertension associated with pulmonary diseases or hypoxia Group 4:Chronic Thromboembolic Pulmonary Hypertension(CTEPH) Group 5: pulmonary hypertension accompanied by unknown multifactorial mechanism 2,Men and women aged 16 years or older 3,WHO function classification 2 or more

Exclusion criteria

Exclusion criteria: 1,Diagnosis of malignant tumor] 2,Diagnosis of myeloproliferative disorder 3,Diagnosis of inflammatory diseases 4,Patients already using pulmonary vasodilator (prostaglandin I 2 preparation, endothelin receptor antagonist, phosphodiesterase 5 inhibitor, soluble guanylate cyclase stimulant)

Design outcomes

Primary

Measure	Time frame
1,All deaths (cardiovascular death / non-cardiovascular death) 2,Exacerbation of pulmonary hypertension 3,If one of the following treatments is required I) Parenteral administration of prostanoid preparations Ii) When it is judged that lung transplantation or atrial atrial septation surgery is necessary at clinician's discretion	—

Secondary

Measure	Time frame
1,Circulatory dynamics index (hemodynamic index by right heart catheterization) 2, Subjective symptoms: questionnaire (SF-36) 3,Serum biomarker 4,Cardiac ultrasound examination 5,Respiratory function test 6,Weight loss and discontinuation of home oxygen therapy (HOT) 7,Hospitalization due to occurrence of adverse event other than hospitalization due to pulmonary hypertension (Hospitalization due to cancer/cerebral infarction/myocardial infarction/left heart failure etc.)	—

Measure

Time frame

1,Circulatory dynamics index (hemodynamic index by right heart catheterization) 2, Subjective symptoms: questionnaire (SF-36) 3,Serum biomarker 4,Cardiac ultrasound examination 5,Respiratory function test 6,Weight loss and discontinuation of home oxygen therapy (HOT) 7,Hospitalization due to occurrence of adverse event other than hospitalization due to pulmonary hypertension (Hospitalization due to cancer/cerebral infarction/myocardial infarction/left heart failure etc.)

—

Countries

Japan

Contacts

Public ContactTakahisa Kondo

Nagoya University Graduate School of Medicine Department of Advanced Medicine of Cardiopulmonary Disease

takahisa@med.nagoya-u.ac.jp052-744-0388

Outcome results